Overview

Immunotherapy has revolutionized cancer treatment. During this session, expert faculty will review important data related to the use of immunotherapy in the neoadjuvant and adjuvant settings. Participants will dive into a comparison of conventional chemotherapy and adjuvant and neoadjuvant immunotherapy, as well as recent FDA approvals in the neoadjuvant setting. 

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Review the critical preclinical data and clinical pharmacology considerations that differentiate immunotherapies within the neoadjuvant and adjuvant treatment settings 

2. Compare and contrast the application of conventional chemotherapy with that of immunotherapy in the neoadjuvant and adjuvant treatment settings

3. Identify the advantages and disadvantages of conventional chemotherapy and immunotherapy when used in the neoadjuvant and adjuvant settings

4. Discuss immunotherapeutics recently FDA-approved in the neoadjuvant setting